Why Do Women Keep Dying from Breast Cancer?: The Role of Automated Breast Ultrasound Screening (ABUS) in Early Detection.-Anupam DattaMajumdar -06/09/2015 - 6:00pm

Event Information
Event Topic: 
Why Do Women Keep Dying from Breast Cancer?: The Role of Automated Breast Ultrasound Screening (ABUS) in Early Detection.
Event Date: 
06/09/2015 - 6:00pm
Event Location: 
Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA
Speaker Information
Event Speaker: 
Anupam DattaMajumdar
Event Speaker Title: 
Vice President of Engineering for U-Systems
Event Speaker Company: 
GE Healthcare
Event Speaker Bio: 

Anupam DattaMajumdar

Anupam DattaMajumdar is Vice President of Engineering for U-Systems, a GE Healthcare company, in Sunnyvale, CA. He earned his Ph.D. in Bioengineering (Medical Imaging) from the University of Washington, his M.S. In Bioengineering (Immunology) from the University of Washington School of Medicine, and a Bachelor of Technology (B.Tech.) in Electrical Engineering from the Indian Institute of Technology, Varanasi. He has held a variety of roles at GE Healthcare including Acoustics Lab Manager, Customer Care Engineering Manager (General Imaging Ultrasound) and General Manager of the Ultrasound Center of Excellence at the John F. (Jack) Welch Technology Centre in Bangalore.

Event Details
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Event Details: 

Breast Cancer is the most common cancer in women worldwide with nearly 1.7 million new cases diagnosed in 2012 (second most common cancer overall). This represents about 12% of all new cancer cases and 25% of all cancers in women.1 It is estimated that worldwide over 508,000 women died in 2011 due to breast cancer.2 Early detection of cancer greatly increases the chances for successful treatment.3

Furthermore, having dense breasts can increase a woman’s risk to develop cancer by 4-6 times.4 Approximately 40% of American women have dense breasts, and it has been shown that mammography may miss over 1/3 of cancers in subjects with dense breasts.5 Outside the USA the situation is more complex. For example, for a variety of reasons routine mammography screening programs commonly available in the USA and other Western societies have not been utilized in China6, where cancers typically occur in younger women and patients have a relatively high incidence of dense breasts.7

This presentation will provide an overview of the clinical problem faced in screening the dense breast population for cancers, and provide an introduction to a GE Healthcare mission to develop effective solutions targeted at this clinical problem. The InveniaTM ABUS (Automated Breast Ultrasound System) is a comfortable, non-ionizing alternative to other supplemental screening options for women with dense breast tissue. When used in addition to mammography, Invenia ABUS can improve detection of invasive breast cancer by a 55 percent relative increase over mammography alone.8
(1) World Cancer Research Fund International
(2) Global Health Estimates, WHO 2013
(3) Ibid
(4) Boyd, N.F., et al. Mammographic Density and the Risk and Detection of Breast Cancer, N Engl J Med 356;3 (2007) 227-236.
(5) Mandelson et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000; 92:1081–1087.
(6) Wu Tsu-Yin, et al. Improving Breast Cancer Outcomes among Women in China: Practices, Knowledge, and Attitudes Related to Breast Cancer Screening. International Journal of Breast Cancer
Volume 2012 (2012)
(7) Wang Feng-Liang et al. Effects of age, breast density and volume on breast cancer diagnosis: a retrospective comparison of sensitivity of mammography and ultrasonography in China’s rural areas.
Asian Pacific Journal of Cancer Prevention, Vol 14, 2013
(8) Brem RF, Tabár L, et.al. Assessing Improvement in Detection of Breast Cancer with Three-dimensional Automated Breast US in Women with Dense Breast Tissue: The SomoInsight Study. Radiology.2015 Mar; 274(3): 663-73.

Brief Statement: The Invenia ABUS is indicated as an adjunct to mammography or breast cancer screening in asymptomatic women for whom screening mammography findings are normal or benign (BI-RADS® Assessment Category 1 or 2), with dense breast parenchyma (BI-RADS Composition/Density 3 or 4), and have not had previous clinical breast intervention. The device is intended to increase breast cancer detection in the described patient population. The Invenia ABUS may also be used for diagnostic ultrasound imaging of the breast in symptomatic women. See the device manual for detailed information, contraindications, warnings, precautions, potential adverse events.

LOGIQ and Invenia are trademarks of General Electric Company or one of its subsidiaries
ACUSON and Sequoia are trademarks of Siemens Medical Solutions USA, Inc. SIEMENS is a trademark by Siemens Aktiengesellschaft in Munchen. BI-RADS is a trademark of the American College of Radiology. Third party trademarks are the property of their respective owners.